Loading...
Loading...
Teva Pharmaceutical Industries
TEVA and Takeda
Pharmaceutical Company
TKPYY today announced the signing
earlier this year of an agreement in which Teva licensed to Takeda the
right to commercialize Teva's innovative glatiramer acetate ( active
ingredient) formulation for the treatment of multiple sclerosis, in
Japan. Teva and Takeda are currently working on further agreements in
connection with the implementation of this license.
Developed by Teva, glatiramer acetate for injection is indicated for the
reduction of the frequency of relapses in relapsing-remitting multiple
sclerosis, including patients who have experienced a first clinical
episode and have MRI features consistent with multiple sclerosis. It is
considered standard treatment for relapsing-remitting multiple
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in